Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Radioimmunotherapy (Y-90 cT84.66), Gemcitabine and Hepatic Arterial Infusion of Fudr for Metastatic Colorectal Carcinoma to the Liver

NCT00645710 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00645710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00645710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Radioimmunotherapy (Y-90 cT84.66), Gemcitabine and Hepatic Arterial Infusion of Fudr for Metastatic Colorectal Carcinoma to the Liver
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
February 11, 2005
Completion date
February 7, 2018
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastases, recurrent colon cancer, recurrent rectal cancer, stage iv colon cancer, stage iv rectal cancer